Upadacitinib Versus Tofacitinib in Anti‐ MDA5 ‐Positive Dermatomyositis With Interstitial Lung Disease: A Multi‐Centre Cohort Study Emulating a Target Trial

Key Points

• This research aims to evaluate the effectiveness of upadacitinib compared to tofacitinib in patients with MDA5-positive dermatomyositis and interstitial lung disease.
• Multi-centre cohort design
• Patient population included MDA5-positive dermatomyositis with interstitial lung disease
• Assessment of lung transplantation-free survival at 6 months
• Upadacitinib was shown to be non-inferior to tofacitinib in improving lung survival by 6 months
• Both treatments displayed comparable safety profiles

Abstract